Issue 48 • February 2022
In association with
Theranos: a wake-up call for the lab-developed test market
Medical devices for rare diseases: the unmet need
3D printing for point-of-care device manufacturing - healthcare hero or hazard?
IQVIA on AI’s potential to match patients to trials and improve trial diversity
UK med tech faces regulatory uncertainty post-Brexit
3D printing will languish in healthcare -until it explodes